Panel Discussion: 1 year in crisis mode

07-Apr-2021 14:46

We have been living with the pandemic for more than a year now. The German biotech industry has developed tests and vaccines in record time. From the industry‘s point of view, what has gone well in the last twelve months and what needs to go better or be improved now in regards of testing, vaccine production and distribution?

Julia Schaft, Managing Director of the BioRN Cluster will discuss these and further questions with her panelists:

  • Kai te Kaat, Vice President, Program Management LS, Qiagen
  • Edgar Fenzl, Managing Director, FGK Clinical Research
  • and Peter Schüßler, Vice President and General Manager, Country Leader Germany Thermo Fisher Scientific

The discussion will take place Thursday 29 April starting 1 pm.

We value your privacy

We and our partners store or access information on devices, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for the purposes described below. You may click to consent to our and our partners’ processing for such purposes. Alternatively, you may click to refuse to consent, or access more detailed information and change your preferences before consenting. Your preferences will apply to this website only. Please note that some processing of your personal data may not require your consent, but you have a right to object to such processing. You can change your preferences at any time by returning to this site or visit our privacy policy.